The sector, she said, was expected to clock revenues of US$5 billion by next year. According to Shaw, it has attained necessary “critical mass” and created a platform for itself that allows it to leapfrog and delivery exponential growth. “India is today becoming the vaccine capital of the world. Bio-manufacturing offers a huge potential and already there are indications that many global contract manufacturers announced they will be shifting their base from Europe to Asia. I think India will be one of the beneficiaries of that particular strategy”, she observed.
Clinical trials, agri-biotech and bio-fuels are becoming big opportunities for India, she said noting that “there are lot of growth drivers and trigger points which we think will deliver in the next five years”.
Bt brinjal
Further, Shaw came in support of Bt brinjal for commercial cultivation in the country.
Stating criticisim was not founded on scientific basis, she said, the opporsition has been basically on unfounded fears, creating a fear psychosis which is quite disturbing. Bt is a very safe science and regulated technology, she said.
Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks